Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Discussions Start for Revision of Ethical GL for Clinical Research
September 3, 2007
- SELF-MEDICATION NEWS IN BRIEF
September 3, 2007
- R&D NEWS IN BRIEF
September 3, 2007
- Daiichi Sankyo Ties Up with Forest Lab. for AZOR
September 3, 2007
- Japan Tissue Engineering's Autologous Epidermis Recommended for Approval
September 3, 2007
- Teijin to Codevelop Ipsen's ITM-077 with Chugai
September 3, 2007
- MEDICAL DEVICE NEWS IN BRIEF
September 3, 2007
- Peptisyntha to Expand Contract Peptide Manufacturing Business in Japan
September 3, 2007
- Drugs Account for 21.7% of Medial Expenditure
September 3, 2007
- Takeda Files MAA for Idebenone in EU
August 27, 2007
- REGULATORY NEWS IN BRIEF
August 27, 2007
- Vice Health Minister Unofficially Meets JGPMA Leaders to Promote Use of Generics
August 27, 2007
- Antidepressant Medication Altered by 40% of Patients: GSK
August 27, 2007
- 47 Programs in PII Trials: Pfizer
August 27, 2007
- Ono Licenses General Anesthetic from CeNeS
August 27, 2007
- 3 Ministries Discuss How to Develop Ventures
August 27, 2007
- Hisamitsu Licenses for Percutaneous Pain Killer from Mundipharma
August 27, 2007
- R&D NEWS IN BRIEF
August 27, 2007
- Toho Pharm., Ohki, and Kokubu to Tie Up
August 27, 2007
- OPINION／Our Attitude Leads to Our Altitude
August 27, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…